Related references
Note: Only part of the references are listed.Atherothrombotic factors and atherosclerotic cardiovascular events: the multi-ethnic study of atherosclerosis
Andrew P. DeFilippis et al.
EUROPEAN HEART JOURNAL (2022)
Lipoprotein(a) reduction with proprotein convertase subtilisin/kexin type 9 inhibitors: An unsolved mystery
Evangelos Liberopoulos
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2021)
Lipoprotein(a) Reduction With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-analysis
Ioannis Farmakis et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2021)
Effect of bariatric surgery on plasma levels of oxidised phospholipids, biomarkers of oxidised LDL and lipoprotein(a)
Jan Hoong Ho et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2021)
Development of an LC-MS/MS Proposed Candidate Reference Method for the Standardization of Analytical Methods to Measure Lipoprotein(a)
Santica M. Marcovina et al.
CLINICAL CHEMISTRY (2021)
Antidiabetic drugs and oxidized low-density lipoprotein: A review of anti-atherosclerotic mechanisms
Ali Ahmadi et al.
PHARMACOLOGICAL RESEARCH (2021)
Lipoprotein(a): Knowns, unknowns and uncertainties
Massimiliano Ruscica et al.
PHARMACOLOGICAL RESEARCH (2021)
PCSK9 Inhibition and Oxidized Phospholipids
Harpreet S. Bhatia et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Lp(a)-Associated Oxidized Phospholipids in Healthy Black and White Participants in Relation to apo(a) Size, Age, and Family Structure
Lars Berglund et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)
Satin therapy increases lipoprotein(a) levels
Sotirios Tsimikas et al.
EUROPEAN HEART JOURNAL (2020)
ApoCIII-Lp(a) complexes in conjunction with Lp(a)-OxPL predict rapid progression of aortic stenosis
Romain Capoulade et al.
HEART (2020)
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
Vera A. Bittner et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Sotirios Tsimikas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The dedicated Lp(a) clinic: A concept whose time has arrived?
Sotirios Tsimikas et al.
ATHEROSCLEROSIS (2020)
Lipoprotein(a) and PCSK9 inhibition: clinical evidence
Massimiliano Ruscica et al.
EUROPEAN HEART JOURNAL SUPPLEMENTS (2020)
Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule
Motasim M. Jawi et al.
JOURNAL OF LIPIDS (2020)
Reduction of myocardial ischaemia-reperfusion injury by inactivating oxidized phospholipids
Calvin Yeang et al.
CARDIOVASCULAR RESEARCH (2019)
Potential Causality and Emerging Medical Therapies for Lipoprotein(a) and Its Associated Oxidized Phospholipids in Calcific Aortic Valve Stenosis
Sotirios Tsimikas
CIRCULATION RESEARCH (2019)
y Phospholipid oxidation products in ferroptotic myocardial cell death
Aleksandra Stamenkovic et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2019)
Current Role of Lipoprotein Apheresis
Gilbert Thompson et al.
CURRENT ATHEROSCLEROSIS REPORTS (2019)
4945Inclisiran-mediated reductions in Lp(a) in the ORION-1 trial
R M Stoekenbroek et al.
EUROPEAN HEART JOURNAL (2019)
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial
Michelle L. O'Donoghue et al.
CIRCULATION (2019)
HEART UK consensus statement on Lipoprotein(a): A call to action
Jaimini Cegla et al.
ATHEROSCLEROSIS (2019)
Actual situation of lipoprotein apheresis in patients with elevated lipoprotein(a) levels
Ulrich Julius et al.
ATHEROSCLEROSIS SUPPLEMENTS (2019)
Effect of Ezetimibe Monotherapy on Plasma Lipoprotein(a) Concentrations in Patients with Primary Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Kamal Awad et al.
DRUGS (2018)
Lipoprotein(a): the perpetual supporting actor
Baris Gencer et al.
EUROPEAN HEART JOURNAL (2018)
NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis
Sotirios Tsimikas et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Association of LPA Variants With Aortic Stenosis A Large-Scale Study Using Diagnostic and Procedural Codes From Electronic Health Records
Hao Yu Chen et al.
JAMA CARDIOLOGY (2018)
Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies A Mendelian Randomization Analysis
Stephen Burgess et al.
JAMA CARDIOLOGY (2018)
Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice
Xuchu Que et al.
NATURE (2018)
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
Peter Willeit et al.
LANCET (2018)
Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels Secondary Analysis of a Randomized Clinical Trial
Romain Capoulade et al.
JAMA CARDIOLOGY (2018)
Oxidized phospholipids and lipoprotein-associated phospholipase A(2) as important determinants of Lp(a) functionality and pathophysiological role
Alexandros D. Tselepis
JOURNAL OF BIOMEDICAL RESEARCH (2018)
Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a)
Alpo Vuorio et al.
EUROPEAN HEART JOURNAL (2017)
Lipoprotein(a): the revenant
Baris Gencer et al.
EUROPEAN HEART JOURNAL (2017)
A Test in Context: Lipoprotein(a) Diagnosis, Prognosis, Controversies, and Emerging Therapies
Sotirios Tsimikas
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Oxidized Phospholipids and Risk of Calcific Aortic Valve Disease The Copenhagen General Population Study
Pia R. Kamstrup et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2017)
Cyclopentenone-containing oxidized phospholipids and their isoprostanes as pro-resolving mediators of inflammation
Olivier Friedli et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2017)
A Replicated, Genome-Wide Significant Association of Aortic Stenosis With a Genetic Variant for Lipoprotein(a) Meta-Analysis of Published and Novel Data
Benjamin J. Cairns et al.
CIRCULATION (2017)
Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials
Amirhossein Sahebkar et al.
BMC MEDICINE (2017)
Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization
Eberhard Roeseler et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)
Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans
Fleur M. van der Valk et al.
CIRCULATION (2016)
The regulation of inflammation by oxidized phospholipids
Stefan Freigang
EUROPEAN JOURNAL OF IMMUNOLOGY (2016)
Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein (a)
Calvin Yeang et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2016)
Thematic Review Series: Lipoprotein (a): Coming of Age at Last Lipoprotein apheresis to treat elevated lipoprotein (a)
Elisa Waldmann et al.
JOURNAL OF LIPID RESEARCH (2016)
Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology
Borge G. Nordestgaard et al.
JOURNAL OF LIPID RESEARCH (2016)
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
Nicholas J. Viney et al.
LANCET (2016)
Heritability of Biomarkers of Oxidized Lipoproteins Twin Pair Study
Fangwen Rao et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study
Sotirios Tsimikas et al.
LANCET (2015)
Impact of Plasma Lp-PLA2 Activity on the Progression of Aortic Stenosis The PROGRESSA Study
Romain Capoulade et al.
JACC-CARDIOVASCULAR IMAGING (2015)
Pathophysiological Role and Clinical Significance of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Bound to LDL and HDL
Constantinos C. Tellis et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease
Harvey D. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Oxidation-specific epitopes and immunological responses: Translational biotheranostic implications for atherosclerosis
Gregor Leibundgut et al.
CURRENT OPINION IN PHARMACOLOGY (2013)
Inflammatory Biomarkers and Cardiovascular Risk Assessment. Current Knowledge and Future Perspectives
Elisavet Moutzouri et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Lipoprotein(a): resurrected by genetics
F. Kronenberg et al.
JOURNAL OF INTERNAL MEDICINE (2013)
Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)
Gregor Leibundgut et al.
JOURNAL OF LIPID RESEARCH (2013)
Oxidation-Specific Biomarkers and Risk of Peripheral Artery Disease
Monica L. Bertoia et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Lipoprotein(a) metabolism: Potential sites for therapeutic targets
Jane Hoover-Plow et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2013)
Lipoprotein(a) Serum Levels in Diabetic Patients with Retinopathy
Giulia Malaguarnera et al.
BIOMED RESEARCH INTERNATIONAL (2013)
Lipoprotein(a) in Cardiovascular Diseases
Michele Malaguarnera et al.
BIOMED RESEARCH INTERNATIONAL (2013)
Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia
Kiyohito Arai et al.
JOURNAL OF LIPID RESEARCH (2012)
Oxidized Phospholipids Are Present on Plasminogen, Affect Fibrinolysis, and Increase Following Acute Myocardial Infarction
Gregor Leibundgut et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Oxidation-Specific Biomarkers, Prospective 15-Year Cardiovascular and Stroke Outcomes, and Net Reclassification of Cardiovascular Events
Sotirios Tsimikas et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events
Adam Taleb et al.
BIOMARKERS IN MEDICINE (2011)
Generation and Biological Activities of Oxidized Phospholipids
Valery N. Bochkov et al.
ANTIOXIDANTS & REDOX SIGNALING (2010)
The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles
Kiyohito Arai et al.
ATHEROSCLEROSIS (2010)
Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages
Y. HASUNUMA et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
A catalogue of reporting guidelines for health research
I. Simera et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2010)
Oxidation-Specific Biomarkers, Lipoprotein(a), and Risk of Fatal and Nonfatal Coronary Events
Sotirios Tsimikas et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
The role of lipoprotein-associated phospholipase A(2) in atherosclerosis may depend on its lipoprotein carrier in plasma
Constantinos C. Tellis et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2009)
Relationship of Oxidized Phospholipids on Apolipoprotein B-100 Particles to Race/Ethnicity, Apolipoprotein(a) Isoform Size, and Cardiovascular Risk Factors Results From the Dallas Heart Study
Sotirios Tsimikas et al.
CIRCULATION (2009)
The oxidized phospholipids linked to human apolipoprotein(a) do not derive from circulating low-density lipoproteins and are probably of cellular origin
Celina Edelstein et al.
FASEB JOURNAL (2009)
The role of oxidized phospholipids in atherosclerosis
Judith A. Berliner et al.
JOURNAL OF LIPID RESEARCH (2009)
Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events
Beate R. Jaeger et al.
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE (2009)
In vivo markers of oxidative stress and therapeutic interventions
Sotirlos Tsimikas
AMERICAN JOURNAL OF CARDIOLOGY (2008)
The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity
Sotirios Tsimikas et al.
CURRENT OPINION IN LIPIDOLOGY (2008)
A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma
Claes Bergmark et al.
JOURNAL OF LIPID RESEARCH (2008)
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent
Emile R. Mohler et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase a2 activity, and 10-year cardiovascular outcomes - Prospective results from the Bruneck study
Stefan Kiechl et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Increased plasma concentrations of lipoprotein(a) during a low-fat, high-carbohydrate diet are associated with increased plasma concentrations of apolipoprotein C-III bound to apolipoprotein B-containing lipoproteins
Min-Jeong Shin et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2007)
Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease - Five-year prospective results from the Bruneck study
Sotirios Tsimikas et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease
S Tsimikas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial
S Tsimikas et al.
CIRCULATION (2004)
Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a) - Short-term and long-term immunologic responses to oxidized low-density lipoprotein
S Tsimikas et al.
CIRCULATION (2004)
Reduced PAF-acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease
LD Tsironis et al.
ATHEROSCLEROSIS (2004)
Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a)
C Edelstein et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes
S Tsimikas et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)
Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase
AD Tselepis et al.
ATHEROSCLEROSIS SUPPLEMENTS (2002)
Share Paper
